Serotonin syndrome: clinical aspects, pathophysiology and treatment

References

1. Oates J. A., Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor // Neurology. – 1960 – (10). – P. 1076–1078.
2. Gerson S. C., Baldessarini R. J. Motor effects of serotonin in the central nervous system // Life Sciences. – 1980 – № 16 (27). – P. 1435–1451.
3. Insel T. R., Roy B. F., Cohen R. M., et al. Possible development of the serotonin syndrome in man // The American Journal of Psychiatry. – 1982 – № 7 (139). – P. 954–955.
4. Sternbach H. The serotonin syndrome // The American Journal of Psychiatry. – 1991 – № 6 (148). – P. 705–713.
5. Bodner R. A., Lynch T., Lewis L., et al. Serotonin syndrome // Neurology. – 1995 – № 2 (45). – P. 219–223.
6. Sporer K. A. The serotonin syndrome. Implicated drugs, pathophysiology and management // Drug Safety. – 1995 – № 2 (13). – P. 94–104.
7. Boyer EW, Traub SJ, Grayzel J. Serotonin Syndrome. Waltham, MA: UpToDate; 2010
8. Volpi-Abadie J., Kaye A. M., Kaye A. D. Serotonin syndrome // The Ochsner Journal. – 2013 – № 4 (13). – P. 533–540.
9. Buckley N. A., Dawson A. H., Isbister G. K. Serotonin syndrome // BMJ (Clinical research ed.). – 2014 – (348). – P. g1626.
10. Мосолов С.Н., Костюкова Е.Г., Сердитов О.В. Серотониновый синдром при лечении депрессии // Международный журнал медицинской практики. 2000. № 8. C. 28-33.
11. Attar-Herzberg D., Apel A., Gang N., et al. The serotonin syndrome: initial misdiagnosis // The Israel Medical Association journal: IMAJ. – 2009 – № 6 (11). – P. 367–370.
12. Prakash S., Rathore C., Rana K., et al. Fatal serotonin syndrome: a systematic review of 56 cases in the literature // Clinical Toxicology (Philadelphia, Pa.). – 2021 – № 2 (59). – P. 89–100.
13. Scotton W. J., Hill L. J., Williams A. C., et al. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions // International Journal of Tryptophan Research : IJTR. – 2019 – (12). – P.1-14 DOI: 10.1177/1178646919873925.
14. Isbister G. K., Buckley N. A. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment // Clinical Neuropharmacology. – 2005 – № 5 (28). – P. 205–214.
15. Mignon L., Wolf W. A. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat // Psychopharmacology. – 2002 – № 1 (163). – P. 85–94.
16. Dunkley E. J. C., Isbister G. K., Sibbritt D., et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity // QJM: An International Journal of Medicine. – 2003 – № 9 (96). – P. 635–642.
17. Foong A.-L., Grindrod K. A., Patel T., et al. Demystifying serotonin syndrome (or serotonin toxicity) // Canadian Family Physician. – 2018 – № 10 (64). – P. 720–727.
18. Racz R., Soldatos T. G., Jackson D., et al. Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis // Clinical and Translational Science. – 2018 – № 3 (11). – P. 322–329.
19. Celada P., Puig M. V., Amargós-Bosch M., et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression // Journal of Psychiatry and Neuroscience. – 2004 – № 4 (29). – P. 252–265.
20. Artigas F. Serotonin receptors involved in antidepressant effects // Pharmacology & Therapeutics. – 2013 – № 1 (137). – P. 119–131.
21. Малин Д.И., Рывкин П.В. Клинически значимые лекарственные взаимодействия при лечении антипсихотиками второго поколения. // Современная терапия психических расстройств. 2021; №2, с. 36-45. DOI: 10.21265/PSYPH.2021.57.2.005
22. Werneke U., Jamshidi F., Taylor D. M., et al. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases // BMC neurology. – 2016 – (16). – P. 97.
23. Culbertson V. L., Rahman S. E., Bosen G. C., et al. Implications of Off-Target Serotoninergic Drug Activity: An Analysis of Serotonin Syndrome Reports Using a Systematic Bioinformatics Approach // Pharmacotherapy. – 2018 – № 9 (38). – P. 888–898.
24. Bijl D. The serotonin syndrome // The Netherlands Journal of Medicine. – 2004 – № 9 (62). – P. 309–313.
25. Rastogi R., Swarm R. A., Patel T. A. Case scenario: opioid association with serotonin syndrome: implications to the practitioners // Anesthesiology. – 2011 – № 6 (115). – P. 1291–1298.
26. Shioda K., Nisijima K., Yoshino T., et al. Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – 2004 – № 4 (28). – P. 633–640.
27. Lee J., Franz L., Goforth H. W. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine // Psychosomatics. – 2009 – № 6 (50). – P. 638–639.
28. Levin T. T., Cortes-Ladino A., Weiss M., et al. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion // General Hospital Psychiatry. – 2008 – № 4 (30). – P. 372–377.
29. Mitchell P. B. Drug interactions of clinical significance with selective serotonin reuptake inhibitors // Drug Safety. – 1997 – № 6 (17). – P. 390–406.
30. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А.Г. Чучалина, В.В. Яснецова; Выпуск XIII. - Москва, 2012.
31. Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике // Современная терапия психических расстройств. 2019. - S1. - С. 2-35. DOI:10.21265/PSYPH.2019.50.40828
32. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А. Г. Чучалина, Ю. Б. Белоусова, В. В. Яснецова /(8-е издание, переработанное и дополненное). Москва, 2007.
33. Steinkellner T., Montgomery T. R., Hofmaier T., et al. Amphetamine action at the cocaine- and antidepressant-sensitive serotonin transporter is modulated by αCaMKII // The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. – 2015 – № 21 (35). – P. 8258–8271.
34. Baldo B. A., Rose M. A. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review // British Journal of Anaesthesia. – 2020 – № 1 (124). – P. 44–62.
35. Tao R., Auerbach S. B. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system // The Journal of Pharmacology and Experimental Therapeutics. – 2002 – № 2 (303). – P. 549–556.
36. Haigler H. J. Morphine: effects on serotonergic neurons and neurons in areas with a serotonergic input // European Journal of Pharmacology. – 1978 – № 4 (51). – P. 361–376.
37. Riblet L. A., Eison A. S., Eison M. S., et al. Buspirone: an anxioselective alternative for the management of anxiety disorders // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – 1983 – № 4–6 (7). – P. 663–668.
38. Mills K. C. Serotonin syndrome. A clinical update // Critical Care Clinics. – 1997 – № 4 (13). – P. 763–783.
39. Muly E. C., McDonald W., Steffens D., et al. Serotonin syndrome produced by a combination of fluoxetine and lithium // The American Journal of Psychiatry. – 1993 – № 10 (150). – P. 1565.
40. Ohman R., Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction // Pharmacopsychiatry. – 1993 – № 6 (26). – P. 263–264.
41. Orlova Y., Rizzoli P., Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome // JAMA Neurology. – 2018 – № 5 (75). – P. 566–572.
42. Jin G., Stokes P. Drug interaction between a selective serotonin reuptake inhibitor and a triptan leading to serotonin toxicity: a case report and review of the literature // Journal of Medical Case Reports. – 2021 – (15). – P. 371.
43. Martin T. G. Serotonin syndrome // Annals of Emergency Medicine. – 1996 – № 5 (28). – P. 520–526.
44. Mason P. J., Morris V. A., Balcezak T. J. Serotonin syndrome. Presentation of 2 cases and review of the literature // Medicine. – 2000 – № 4 (79). – P. 201–209.
45. Isbister G. K., Buckley N. A., Whyte I. M. Serotonin toxicity: a practical approach to diagnosis and treatment // Medical Journal of Australia. – 2007 – № 6 (187). – P. 361–365
46. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А.Г. Чучалина, выпуск IV, - Москва, 2003.
47. Gillman P. K. The serotonin syndrome and its treatment // Journal of Psychopharmacology (Oxford, England). – 1999 – № 1 (13). – P. 100–109.
48. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А. Г. Чучалина, Ю. Б. Белоусова, В. В. Яснецова. Москва, 2009. (9-е издание, переработанное и дополненное)
49. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А. Г. Чучалина, Ю. Б. Белоусова, В. В. Яснецова. Москва, 2006. (7-е издание, переработанное и дополненное)
50. Nisijima K., Shioda K., Yoshino T., et al. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome // Neurochemistry International. – 2003 – № 2 (43). – P. 155–164.
51. Krishnamoorthy S. Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain // Basic & Clinical Pharmacology & Toxicology. - 2010. - № 4 (107). - Р. 830–841.
52. Dvir Y., Smallwood P. Serotonin syndrome: a complex but easily avoidable condition // General Hospital Psychiatry. – 2008 – № 3 (30). – P. 284–287.
53. Boyer E. W., Shannon M. The Serotonin Syndrome // New England Journal of Medicine. – 2005 – № 11 (352). – P. 1112–1120.
54. Nisijima K., Shioda K., Yoshino T., et al. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome // Pharmacopsychiatry. – 2004 – № 2 (37). – P. 57–62.
55. Nisijima K., Yoshino T., Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome // Psychopharmacology. – 2000 – № 1 (150). – P. 9–14.
56. Nisijima K., Yoshino T., Yui K., et al. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome // Brain Research. – 2001 – № 1 (890). – P. 23–31.
57. Graudins A., Stearman A., Chan B. Treatment of the serotonin syndrome with cyproheptadine // The Journal of Emergency Medicine. – 1998 – № 4 (16). – P. 615–619.
58. Baigel G. D. Cyproheptadine and the treatment of an unconscious patient with the serotonin syndrome // European Journal of Anaesthesiology. – 2003 – № 7 (20). – P. 586–588.
59. Lappin R. I., Auchincloss E. L. Treatment of the serotonin syndrome with cyproheptadine // The New England Journal of Medicine. – 1994 – № 15 (331). – P. 1021–1022.
60. McDaniel W. W. Serotonin syndrome: early management with cyproheptadine // The Annals of Pharmacotherapy. – 2001 – № 7–8 (35). – P. 870–873.
61. Horowitz B. Z., Mullins M. E. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion // Pediatric Emergency Care. – 1999 – № 5 (15). – P. 325–327.
62. Gutknecht L., Kriegebaum C., Waider J., et al. Spatio-temporal expression of tryptophan hydroxylase isoforms in murine and human brain: convergent data from Tph2 knockout mice // European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. – 2009 – № 4 (19). – P. 266–282.
63. Kim J. J., Wang H., Terc J. D., et al. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation // American Journal of Physiology. Gastrointestinal and Liver Physiology. – 2015 – № 6 (309) – P. 455-465.
64. Liu Q., Yang Q., Sun W., et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract // The Journal of Pharmacology and Experimental Therapeutics. – 2008 – № 1 (325). – P. 47–55.
65. Kvols L. K. Metastatic carcinoid tumors and the malignant carcinoid syndrome // Annals of the New York Academy of Sciences. – 1994 – (733). – P. 464–470.
66. Molina-Cerrillo J., Alonso-Gordoa T., Martínez-Sáez O. et al. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors // The Oncologist. – 2016 – № 6 (21). – P. 701–707
67. Zimmer L., Luxen A., Giacomelli F., et al. Short- and long-term effects of p-ethynylphenylalanine on brain serotonin levels // Neurochemical Research. – 2002 – № 4 (27). – P. 269–275.
68. Parker V., Wong A. H., Boon H. S., et al. Adverse reactions to St John’s Wort // Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. – 2001 – № 1 (46). – P. 77–79.
69. Beckman S. E., Sommi R. W., Switzer J. Consumer use of St. John’s wort: a survey on effectiveness, safety, and tolerability // Pharmacotherapy. – 2000 – № 5 (20). – P. 568–574.
70. Rahman S. Z., Basilakis J., Rahmadi A., et al. Use of serotonergic antidepressants and St John’s wort in older Australians: a population-based cohort study // Australasian P sychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists. – 2013 – № 3 (21). – P. 262–266.
71. Lantz M. S., Buchalter E., Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly // Journal of Geriatric Psychiatry and Neurology. 1999. № 1 (12). C. 7–10.
72. Hardy M., Panikkar G. A Case of Serotonin Syndrome in the Setting of Dextromethorphan-Based Cough Medicine, Tramadol, and Multiple Antidepressants // The Primary Care Companion for CNS Disorders. – 2020 – № 2 (22). – P. 10–15
73. DeSilva K. E., Le Flore D. B., Marston B. J., et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine // AIDS. – 2001 – № 10 (15). – P. 1281
74. Mas Serrano M., Pérez-Sánchez J. R., Portela Sánchez S., et al. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir // Journal of the Neurological Sciences. – 2020 – (415). – P. 116944.
75. Психофармакологические и противоэпилептические препараты, разрешенные к применению в России. / Под ред. С.Н. Мосолова / Издание 2-е, исправленное и переработанное. - Москва, 2004.
76. Мосолов С.Н., Костюкова Е.Г. Актуальные вопросы фармакотерапии депрессий. В книге: Новые достижения в терапии психических заболеваний. / Под ред. С.Н Мосолова / Москва, 2002. - С. 211-231.
77. Ramos M., Berrogain C., Concha J., et al. Pharmacogenetic studies: a tool to improve antidepressant therapy // Drug Metabolism and Personalized Therapy. – 2016 – № 4 (31). – P. 197–204.